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Background: MicroRNAs are small non-coding RNAs that regulate gene expression at the post-transcriptional level.
While they have been implicated in various diseases, the profile changes in allergen inhalation challenge are not
clarified in human. We aimed to evaluate changes in the microRNA profiles in the peripheral blood of asthmatic
subjects undergoing allergen inhalation challenge.
Results: Seven mild asthmatic subjects participated in the allergen inhalation challenge. In addition, four healthy
control subjects (HCs) were recruited. MicroRNA profiles in peripheral blood samples (pre-challenge and 2 hours
post-challenge) were measured by the NanoString nCounter assay to determine changes in miRNA levels as these
asthmatic subjects underwent an allergen inhalation challenge. One common miRNA, miR-192, was significantly
expressed in both comparisons; HCs vs. pre-challenge and pre- vs. post-challenge, showing that miR-192 was
significantly under-expressed in asthmatics compared to HCs and decreased in post-challenge at an FDR of 1%.
Cell-specific statistical deconvolution attributed miR-192 expression in whole blood to PBMCs. MiR-192 was
technically validated using real-time reverse transcription-quantitative polymerase chain reaction (RT-qPCR) showing
that the level in asthmatics (pre-challenge) was significantly lower than HCs and that post-challenge was
significantly lower than pre-challenge. The normalized relative miR-192 expression quantified using RT-qPCR specific
to PBMCs was also validated. Ontology enrichment and canonical pathway analyses for target genes suggested
several functions and pathways involved in immune response and cell cycle.
Conclusions: The miRNA profile in peripheral blood was altered after allergen inhalation challenge. Change in
miR-192 levels may be implicated in asthma mechanisms. These results suggest that allergen inhalation challenge
is a suitable method to characterize peripheral miRNA profiles and potentially elucidate the mechanism of human
asthma.
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Exposure to allergen is one of the important factors to
induce and enhance asthma pathogenesis, which is char-
acterized by reversible bronchoconstriction, airway
hyperresponsiveness and airway inflammation. Allergen
inhalation challenge is a useful model to investigate the
pathogenesis of allergic airway diseases [1]. The asth-
matic response can be evaluated by airflow limitation
which can be measured as forced expiratory volume in 1
second (FEV1) drop using a spirometer. Recently, we
have reported differential changes in the gene expression
of peripheral blood leukocytes in atopic asthmatic indivi-
duals 2 hours following allergen inhalation challenge [2],
indicating the application of gene expression in blood
for assessing the asthmatic response. As blood is the
pipeline of the immune system, assessing changes in ex-
pression profiles gives a comprehensive view of the sta-
tus of the immune system in health and disease [3].
Since allergen exposure triggers immune responses, in-
cluding the production of various mediators, inflamma-
tory cell proliferation and infiltration in the human
body, the immune cells and their gene expression can be
good exploratory targets to understand the mechanisms
of the asthmatic response to allergen inhalation
challenge.
MicroRNAs (miRNAs) are a class of small noncoding
RNAs with a regulatory function on gene expression to
control various biological processes such as cellular pro-
liferation, apoptosis and differentiation. They have been
implicated in the pathogenesis of malignancy, cardiovas-
cular and other diseases [4]. Several studies have previ-
ously reported the role of miRNAs in asthma using the
allergen inhalation challenge model. In the lung, miRNA
profiles were significantly changed in the experimental
mouse model mimicking acute and chronic human
asthma [5,6]. In humans, while a study comparing the
miRNA profile of airway biopsies revealed no significant
difference in the expression of 227 miRNAs between
mild asthmatics compared to healthy volunteers [7], a
more recent study on cultured human bronchial epithe-
lial cells revealed inherent differences in the expression
of miRNAs isolated from healthy and asthmatic subjects
[8]. Changes in miRNA profiles have not been clarified
in the human asthmatic response during the allergen in-
halation challenge. In this study, we focused on the
miRNA profiles in human peripheral blood and
hypothesized that miRNA profiles altered by allergen in-
halation challenge can be detected in peripheral blood.
Results
Subjects characteristics
Seven subjects with stable, mild atopic asthma partici-
pated in the allergen inhalation challenge. Four healthy
control subjects (HCs) were recruited to serve ascontrols. The demographics of seven subjects with mild
atopic asthma and four HCs are presented in Table 1.
All asthmatic subjects developed an immediate drop in
FEV1 of greater than 20% (Additional file 1: Figure S1).
Processing of peripheral blood for miRNA Panel Codeset
Peripheral blood was drawn immediately before (pre)
and after allergen inhalation (post) from asthmatics. Per-
ipheral blood from HCs was collected as controls.
Extracted RNA was analysed using NanoString nCounter
assay. One hundred and sixty-three of the 734 miRNAs
profiled using the NanoString nCounter assay were
above background across all samples. The data set was
normalized to the sum of the 163 miRNAs, such that
each sample had the same total miRNA code count.
MiRNAs above at least 100 code counts were retained
for downstream analysis. The dataset (72 miRNAs for 18
samples) underwent log2 transformation prior to statis-
tical analysis.
Differentially expressed miRNA in NanoString nCounter
assay
Two independent linear models were used to determine
significant miRNAs for the two comparisons; HCs versus
pre-challenge, and pre versus post-challenge. MiR-192
was significant in both comparisons at a false discovery
rate (FDR) of 1% (Figure 1). MiR-192 was down-
regulated in both comparisons (Figure 2A), that is, miR-
192 was significantly under-expressed in asthmatics
(pre-challenge) compared to HCs and decreased follow-
ing allergen inhalation challenge.
MiR-192 expression in peripheral blood mononuclear
cells (PBMCs)
Given the heterogeneous nature of whole blood, changes
in miRNA expression may not be due to changes in
miRNA expression in specific cells but due to changes
in the relative cell-type frequencies. Leukocyte differen-
tials were significantly different among the three groups,
while complete blood counts such as erythrocytes, total
leukocytes and platelets were not significantly different
among groups (Table 2). In order to determine whether
miR-192 expression was associated with certain cell-type
frequencies, a multiple regression of miR-192 expression
onto the cell-type frequencies was performed for each
group (HC, pre and post) independently. Given the small
sample size of HCs (n=4), the neutrophils, eosinophils
and basophils were combined (added) to form a granulo-
cyte group whereas the lymphocytes and monocytes
were combined into a peripheral blood mononuclear
cells (PBMCs) group. The regression coefficients
representing the mean miR-192 expression for granulo-
cytes and PBMCs were extracted for each group
(Additional file 1: Figure S2). In order to determine
Table 1 Demographics of subjects







1 28 F Cat Pelt 12.8 ND ND
2 34 F Cat Pelt 2.7 6.1 0.44
3 27 M Cat Pelt 4.5 1.8 2.5
4 42 F Cat Hair 5.3 8.6 0.62
5 23 F Cat Hair 0.3 0.2 1.5
6 26 F Cat Hair 5.1 1.5 3.4
7 49 F Cat Hair 3.6 1 3.6
Mean ±SE 32.7±3.3 3.3† 1.7† 2.0±0.5
Healthy controls
1 33 F ND
2 43 F ND
3 21 M ND
4 43 M ND
Mean ±SE 35.0±4.5
ND - Not determined, SE: standard error of the mean, †: geometric mean (PC20 values are measured on a log scale).
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significantly different between groups, a test-statistic for
each cell-type between two independent groups was cal-
culated (see Methods). This statistic compares whether
the slopes for two independent groups are different for
the same cell-type: that is, for the same increase in a
particular cell frequency, is the increase in the mean
miRNA expression greater in one group that the other.
This increase is independent of changes in other cellular
frequencies. MiR-192 expression at the same frequency








Figure 1 Volcano plot of statistical significance against fold-change o
asthmatics (pre-challenge) and between pre and post-challenge. Dash(pre- and post-challenge), however, the mean miR-192
expression was significantly (p=0.012) higher in HCs
than in asthmatics (pre-challenge) for the same fre-
quency of PBMCs independent of the frequency of gran-
ulocytes (Figure 2B). Additional file 1: Figure S3 shows
the empirical distributions for these comparisons for
1000 permutations. This may suggest that the decrease
in miR-192 seen in whole blood (Figure 2A) may be due
to a decrease in miR-192 expression in PBMCs inde-
pendent of changes in the frequency of granulocytes.
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Figure 2 MiR-192 expression in whole blood and in peripheral blood mononuclear cells (PBMCs). A. MiR-192 expression in whole blood.
B. Cell-specific miR-192 expression in granulocytes (gray bar) and PBMCs (white bar) comparing healthy control (HC) and asthmatics pre and
post-challenge (Pre, Post).
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whole blood (Figure 2A), this change was not significant.Technical validation using real-time reverse transcription-
quantitative polymerase chain reaction (RT-qPCR)
MiR-192 was technically validated (Figure 3A) using
RT-qPCR showing that the level in asthmatics (pre-
challenge) was significantly (p < 0.05) lower than HCs
and that post-challenge was significantly lower than pre-
challenge.
The normalized relative miR-192 expression quantified
using RT-qPCR was also regressed onto the relative cell-
type frequencies of granulocytes and PBMCs for HC and
pre-challenge in separate linear models. The regression
coefficient for PBMCs in healthy individuals (i.e. miR-
192 expression in PBMCs in HC) was significantly
(p=0.036) higher than the regression coefficient for
PBMCs in asthmatics at pre-challenge (i.e. miR-192Table 2 Complete blood count and leukocyte differentials for
Healthy controls Pre-challenge
Complete blood count
Erythrocytes (1012/L) 4.41 (0.17) 4.36 (0.08)
Platelets (109/mL) 246 (18) 258 (37)
Leukocytes (109/mL) 5.48 (0.84) 6.10 (0.35)
Leukocyte differentials
Neutrophils (%) 56.4 (7.8) 57.9 (4.5)
Lymphocytes (%) 29.6 (5.5) 29.5 (4.4)
Monocytes (%) 4.5 (0.7) 7.4 (0.7)
Eosinophils (%) 2.1 (0.6) 4.7 (0.8)
Basophils (%) 5.6 (5.5) 0.5 (0.1)
HC, healthy controls. pre, pre-challenge (asthmatics). post, post-challenge (asthmatiexpression in PBMCs in asthmatics at pre-challenge)
(Figure 3B).
Genes up-regulated in allergen inhalation challenge and
targeted by miR-192
To clarify the suggestive mechanisms of miR-192 in al-
lergen inhalation challenge, genes targeted by miR-192
were retrieved from the list of differentially expressed
genes between pre- and 2 hour post-allergen challenge,
which Kam et al. reported in their manuscript [2].
Among 80 genes which were significantly altered and
predicted as target genes for miR-192 by databases mi-
Randa and TargetScan, 56 genes were up-regulated while
24 genes were down-regulated post-challenge. To clarify
the biological mechanisms, we performed network mod-
eling using MetaCore from GeneGo (St Joseph, MI,
USA), allowing us to build a candidate network indicat-
ing possible interactions between genes. The Functional
Ontology Enrichment tool, which was used for analysingtwo comparisons
Post-challenge P-value HC vs. pre P-value pre vs. post
4.40 (0.08) 0.786 0.361
273 (36) 0.759 0.084
6.91 (0.37) 0.199 0.071
65.0 (2.6) 0.782 0.012*
25.6 (2.6) 0.989 0.120
5.7 (0.8) 0.042* 0.013*
3.3 (0.7) 0.077 0.002*
0.4 (0.1) 0.002* 1.000
cs). Values reported as mean (standard error of the mean). *: p < 0.05.



































Figure 3 Technical validation of miR-192 expression in whole blood and PBMCs. A. MiR-192 expression quantified using RT-qPCR in whole
blood. B. MiR-192 expression in PBMCs comparing healthy control (HC) and asthmatics (pre-challenge).
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onto terms of a given MetaCore ontology, showed a
number of significant (p<0.01) inflammatory pathways
such as ChREBP regulation pathway and IFNα/β signal-
ling pathway (Additional file 1: Table S1). Similarly, the
list of up-regulated target genes was used to generate
biological networks using the Canonical Pathway Model-
ing algorithm. Additional file 1: Table S2 shows the list
of networks that are highly enriched with canonical
pathways. The results comprise network objects corre-
sponding to genes and other interacting objects in ca-
nonical pathways found in databases. For the top two
highly enriched pathways, one pathway was related to
DNA damage and cell cycle regulation (Additional file
1: Figure S4A) and the other pathway was related to
immunological response and stress response (Additional
file 1: Figure S4B).
Discussion
We analysed for the first time the change in miRNA
profiles of human asthmatics undergoing allergen inhal-
ation challenge as well as the difference in miRNA pro-
files between pre-level in asthmatics and healthy control
subjects without asthma history. MiR-192 was signifi-
cantly lower in post-allergen inhalation challenge com-
pared to pre-challenge, as well as lower in asthmatics
compared to healthy control subjects, suggesting that
the change in miR-192 level may be involved in the
atopic asthma and asthmatic reaction after allergen in-
halation challenge. Cell specific expression of miR-192
was associated with peripheral blood mononuclear cells
(PBMCs). Among the genes we have previously reported
to be altered following allergen inhalation challenge [2],
predicted target genes of miR-192 were largely up-
regulated suggesting the inhibitory role of miR-192 ontheir expression. The result showing that these target
genes were enriched for the functions on cell cycle and
immune response supports the notion that miRNA can
regulate such biological functions in the asthmatic
response.
MiR-192 has been studied in various conditions in-
cluding cancer and autoimmune diseases. Several reports
showed that miR-192 affects cellular proliferation
through the p53 pathway, which regulates cell cycle. The
cell cycle checkpoint control genes, p53 and p21 were
overexpressed in cells with overexpressed miR-192
in vitro using human cell lines [9]. In the canonical path-
way modeling in our results for the up-regulated target
genes for miR-192, cell cycle regulation and response to
DNA damage was one of the top-listed pathways, sug-
gesting that miR-192 mediates cell cycle regulation of
blood cells in response to allergen challenge. In the
other study investigating the response of miRNA to en-
vironment, exposure to cigarette smoke decreased miR-
192 expression in the lung in animal experimental model
[10]. Given that the cigarette smoke exposure induces
airway inflammation and cellular stress such as oxidative
stress, this report supports our findings that miR-192 is
regulating the response to miRNAs to environmental ex-
posure inducing airway inflammation. As shown in the
other top-listed pathway in the canonical pathway mod-
eling in our data, miR-192 was suggested to mediate the
immune response following allergen inhalation. In
addition, as a biomarker in peripheral blood, miR-192
has been reported to decrease in systemic lupus erythe-
matosus, a systemic autoimmune disease inducing in-
flammatory responses [11]. Perturbation of miRNA
profiles in response to inflammatory stimuli can occur
in peripheral blood and the changes can be detected.
Interestingly, miR-192 expression is also reportedly
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correlates with tubulointerstitial fibrosis and reduction
in renal function in renal biopsies from patients with
established diabetic nephropathy [12]. Allergen inhal-
ation challenge induces up-regulation of TGF-β in the
airway epithelium [13]. TGF-β has been implicated in
airway remodeling and inflammation, which are features
of chronic asthma. Although the origin of the miRNA
needs to be clarified, our data showing down-regulated
miR-192 in the blood after allergen inhalation challenge
may indicate similar TGF-β derived mechanisms. Since
the mechanism of miR-192 has not been elucidated in
allergic airway diseases, further studies are needed to
clarify these mechanisms.
Peripheral blood consists of various types of cells such
that the expression of a given miRNA is the net expres-
sion from all the various cell-types. In this report, statis-
tical methods for deconvolving cell-specific miRNA
levels from whole blood experiments were used. This ap-
proach called cell-specific significance analysis of micro-
arrays (csSAM) [14] can combine information from
complete blood cell count, including leukocyte differen-
tials, and whole blood gene expression data to decon-
volve cell specific expression measurements that can
then be compared across groups. We have previously
shown that csSAM can uncover cell-specific gene ex-
pression signatures in whole blood in two independent
studies [15,16]. We utilized this approach to analyse
cell-specific analysis for miR-192 expression in granulo-
cytes and PBMCs. The difference of miR-192 levels is
suggested to be derived from PBMCs in our data, sug-
gesting that further studies on the subtype of lympho-
cytes and monocytes will help reveal the mechanisms of
miRNA in asthma and asthmatic responses as well.
MiR-192 levels are reportedly different among subsets of
lymphocytes [17]. A study comparing miRNA expression
in a wide range of haematological cell lines showed that
miR-192 was up-regulated in activated B cells [18]. Al-
lergen challenge induces a dynamic shift of lymphocyte
populations in blood. 24 hours after challenge there was
a reduction of peripheral blood CD4+ T lymphocytes
from a baseline whereas CD4+ T lymphocytes in bronch-
oalveolar fluid increased, suggesting lymphocyte recruit-
ment into the respiratory system after allergen challenge
[19,20]. In a baseline comparison between asthmatics
and healthy controls, while there was no significant dif-
ference in number of T cells or B cells in peripheral
blood [21,22], their subpopulations and activation state
have been reported to be different. Several studies inves-
tigating peripheral blood cells in mild asthma also
showed the increase in the number of activated popula-
tion such as CD23-bearing B cells and CD25-bearing T
cells in mild atopic asthmatics as well as low number of
gamma delta T cells in the peripheral blood ofasthmatics [22,23]. Given that cell populations and sub-
populations can affect the miRNA levels, it is necessary
to clarify the relationship between such cellular popula-
tions and differential miRNA profiles, for example
through the use of statistical deconvolution methods
such as csSAM.
The csSAM test statistic which compares the mean
miRNA expression for each cell type between two inde-
pendent groups does not take into account the paired
structure of our longitudinal study design. Since it is pos-
sible to achieve statistical significance with smaller treat-
ment effects in a paired study design, using an unpaired
test statistic may explain why the reduction of miR-192 ex-
pression in PBMCs post-challenge compared to pre-
challenge was not statistically significant (Figure 2B).
Accounting for the within individual variation through the
use of a mixed-effects model or multilevel data analysis
with a modification to the csSAM test statistic may help
improve the statistical significance of the csSAM test statis-
tic in longitudinal studies. The small number of subjects
limited the number of cell-types for cell-specific analyses in
this study. Future studies with larger sample size will enable
us to further study the role of additional cell types. In
addition we have not compared the phenotypes induced by
allergen inhalation challenge such as early responders and
dual responders. The current analyses comparing pre and
post combined these phenotypes, which may serve as con-
founding factors. Given the sample size a technical valid-
ation with RT-qPCR was deemed appropriate. Given the
course of allergen inhalation challenge, a longer time
course study of miRNA levels in blood in both asth-
matics and healthy subjects also needs to be explored.
Collectively, a further study using a different cohort con-
sisting of a large sample size is needed to validate the de-
crease in miR-192 levels in asthmatics after allergen
inhalation challenge. Thereafter, cell-specific approaches
for differential miRNAs will also validate our results as
well as shed light on further mechanisms of miRNAs in
certain cell types in peripheral blood cells.
Conclusion
MiRNA profile changes can be detected in peripheral
blood of asthmatic subjects undergoing allergen inhal-
ation challenge and between healthy control and asth-
matics. Among them, changes in miR-192 level may be
involved in asthma mechanisms. These results indicate
that allergen inhalation challenge can be a suitable
model to explore miRNA profiles and help elucidate the
mechanisms of allergic asthma in humans.
Methods
Subjects and allergen inhalation challenge
This study was approved by University of British
Columbia-Providence Health Care Research Ethics Board
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local Research Ethics Boards. Seven subjects with stable,
mild atopic asthma participated in the allergen inhalation
challenge. Four HCs were recruited to serve as controls. All
subjects were non-smokers, free of other lung diseases, and
not pregnant. Diagnosis of asthma was based on the Global
Initiative for Asthma criteria. Asthmatic subjects were diag-
nosed as mild allergic asthma, and only used intermittent
short-acting bronchodilators for treatment of their asthma.
Asthmatic subjects had a baseline FEV1 ≥70% of predicted,
and the provocative concentration of methacholine
required to produce a 20% decrease in FEV1 (PC20)
was ≤16 mg/mL [24]. The methacholine inhalation chal-
lenge was conducted as described by Cockcroft [25,26].
Skin prick tests were used to determine allergies to cat, and
the dose of cat extract for inhalation. Allergen challenges
were conducted as triad visits. On the first and third days,
subjects underwent methacholine challenges for assess-
ments of airway hyperresponsiveness, and on the second
day subjects underwent allergen inhalation challenges as
described by O’ Byrne et al. [27], using extracts of cat pelt
or hair. Asthmatic subjects were challenged with cat aller-
gen to reduce confounding effects of different types of aller-
gens. Blood was drawn immediately before (pre) and
approximately 2 hours after allergen inhalation (post). Per-
ipheral blood from HCs was collected in the morning
(9 a.m.) to accommodate the time point comparing to pre-
level of asthmatic subjects.
Blood collection and RNA extraction
Peripheral venous blood samples were collected into BD
Vacutainer plastic EDTA tubes (Becton, Dickinson and
Company, Franklin Lakes, NJ, USA). One aliquot was
processed for total and differential cell counts, and the
other aliquot was frozen and stored at −80°C until RNA
extraction. From thawed samples, total RNA containing
miRNA was purified from 400 μL of whole blood
according to manufacturer’s protocols using the RNeasy
Mini Kit (Qiagen, Chatsworth, CA, USA). The yield and
quality of RNA were assessed by NanoDrop 8000 Spec-
trophotometer (Thermo Scientific, Wilmington, DE,
USA) and Agilent 2100 Bioanalyzer (Agilent Technolo-
gies, Santa Clara, CA, USA).NanoString nCounter assay
Comprehensive assay for miRNA expression was per-
formed using nCounterW miRNA Expression Assay Kits
(NanoString Technologies, Seattle, WA, USA) at Nano-
String Technologies. In this method, the novel technol-
ogy which enabled multiplexed direct digital counting of
RNA molecules [28] were applied to miRNAs with some
modification. Briefly, to prepare a miRNA molecule for
hybridization in the nCounter assay, a proprietary DNAsequence called miRtag is ligated to the mature miRNA
using a bridging oligonucleotide (bridge). The miRtags
for the human miRNA are ligated and bridges are puri-
fied in one simple multiplexed reaction. After removal of
the bridge, the tagged mature miRNA is then hybridized
to a colour-coded reporter probe and a biotinylated cap-
ture probe. The capture probe allows the complex to be
immobilized for data collection with measurement of its
colour code. A total of 734 human and human-
associated viral miRNAs were simultaneously assayed.
NanoString nCounter miRNA assay protocol
MiRNA assays were performed using 100 ng of total
RNA following the standard nCounter miRNA Assay
Protocol. Hybridizations were carried out by mixing 5 μl
of each miRNA assay with 20 μl NanoString nCounter
reporter probe and 5 μl capture probe (30 μl total reac-
tion volume) and incubating the hybridizations at 65°C
for 18 hours.
Preprocessing of miRNA Panel Codeset
The nCounter assay for each sample consisted of six
positive controls (0.125-128 fM), eight negative controls,
five control mRNAs (ACTB, B2M, GAPDH, RPL19 and
RPLP0) and 734 miRNAs. Prior to normalization several
probes in the codeset required background subtraction
(Additional file 1: Table S3). The probes for which the
background subtraction calculation produced a negative
number were set to 1 for simplicity. To account for
slight differences in assay efficiency (hybridization, puri-
fication, and binding) the data was normalized to the
sum of 6 positive RNA spike-in controls. For each sam-
ple, the mean plus 2 times the standard deviation of the
8 negative controls was subtracted from each miRNA
count in that sample. Only miRNAs with non-negative
counts across all samples were retained for downstream
analysis.Technical validation using RT-qPCR
RT-qPCR was carried out using the TaqMan MiRNA
Assay (Applied Biosystems, Foster City, CA) according
to the manufacturer's protocol. RNA samples were mea-
sured in duplicates. The TaqMan MicroRNA Reverse
Transcription Kit (Applied Biosystems) was used for the
preparation of cDNA. Reverse transcription reactions
were performed in a volume of 15 μl, and each reaction
contained 10 ng of total RNA including miRNA. The
PCR reaction mix consisted of the RT product, TaqMan
2X Universal PCR Master Mix and the appropriate 5X
MicroRNA Assay Mix containing primers and probe for
the miRNA of interest. All TaqMan assays were run in
duplicate on an ABI Prism 7900, applying 40 PCR cycles.
Ct values were calculated with the SDS software using
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ered to be below the detection level of the assay. RNU44
and RNU6B were used for normalizing the expression
level of selected miRNAs. The mean of Ct values was
subtracted from the corresponding Ct value for the
selected miRNAs resulting in the ΔCt value which was
used for relative quantification of miRNA expression.
Statistical analysis
Complete blood cell count and leukocyte differentials
were compared among groups using analysis of variance.
Moderated robust regression in the Linear Model for
Microarrays (limma) library from bioconductor was used
to determine statistically significant miRNAs using a
Benjamini Hochberg FDR of 1% [29]. A p-value of 0.05
was used to determine significant changes in cell counts.
Significant cell-specific miRNA expression was deter-
mined using methods as previously described [14]. For
each group, regression of miRNA expression onto the
relative cell-type frequencies was used to determine the
mean miRNA expression for each cell-type:
1. Multiple regression of miRNA expression onto the
relative cell-type frequencies for each group g.
yg ¼ β0 þ β1gx1g þ    þ βkgxkg þ εg ¼ Xβþ ε;
β0g = 0; implies that at zero cell-type frequency there
is zero miRNA expression.
βkg; increase in miRNA expression for 1% increase in
the kth cell-type frequency in group g (mean miRNA
expression in the kth cell-type in group g)
yg; vector of miRNA expression values for group g
xkg: vector of relative cell-type frequencies for the k
th
cell-type for group g
2. Test statistic to determine significant changes in cell-
specific miRNA expression.
Similar to the Wald test to determine significant
covariates, the following test statistic was used to
determine significant miRNA expression changes in
the kth cell between two groups.
Test statistic comparing group 1 and group 2 for the
kth cell-type:
















The p-value for each test-statistic was calculated by
generating an empirical distribution by recalculating
test-statistics after reshuffling of class labels 1000
times. A p-value of 0.05 was deemed significant.Target prediction, gene ontology analysis and canonical
pathway analysis
Target genes for miR-192 were predicted using data-
bases, miRanda and TargetScan to list the targets identi-
fied by both. Then the target genes for miR-192 were
selected out of 1595 differentially expressed genes, which
were identified post-allergen inhalation challenge at an
FDR of 5% by Kam et al. [2].
Signalling pathways and cellular processes for target
genes, which were reportedly up-regulated in post-
allergen challenge and predicted to be targeted by miR-
192, were defined through GeneGo MetaCore databases:
Functional Enrichment by Ontology and Canonical
Pathway Modeling.
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